Theresa Heggie

Theresa Heggie was appointed to the Board in November 2018, bringing more than 30 years of experience as a business leader in the pharmaceutical, biotechnology, and rare disease industries. After joining as Chief Commercial Officer, Ms. Heggie most recently served as Chief Operating Officer of ProQR, a company developing RNA therapies using its proprietary Axiomer RNA-editing platform technology for severe, rare & common diseases. Ms. Heggie previously served on the ProQR Supervisory Board from 2019-2021. Prior to joining ProQR in 2021, Ms. Heggie was CEO of Freeline and before that was Senior Vice President, Head of Europe, Middle East and Africa, and Canada for Alnylam Pharmaceuticals, Global Chief Strategy and Marketing Officer for Bupa, and before that, Senior Vice President of Global Commercial Operations for Shire Human Genetic Therapies (HGT).